Sanofi
SNYNFOTC
SNYNF·OTC
Sanofi is a global pharmaceutical and healthcare enterprise dedicated to the discovery, development, manufacturing, and commercialization of therapeutic solutions, serving patients and consumers across the United States, Europe, and various international territories. Its business activities are structured across three primary segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The Pharmaceuticals division delivers a broad portfolio of specialty care products. These encompass cutting-edge human monoclonal antibodies, alongside treatments for complex conditions like multiple sclerosis, neurological issues, diverse inflammatory and immunological ailments, rare diseases, oncology, and rare blood disorders. Furthermore, this segment provides medications for diabetes and cardiovascular health, as well as a range of established prescription drugs. Sanofi's Vaccines division is a key provider of vital immunizations. Its offerings include pediatric vaccinations against poliomyelitis, pertussis, and Hib, alongside adult vaccines for influenza, booster shots, meningitis, and specialized immunizations for travel and endemic areas. Through its Consumer Healthcare segment, the company markets a diverse assortment of over-the-counter remedies. These solutions address areas such as allergy relief, cough and cold symptoms, pain management, liver care, physical and mental wellness, probiotics, digestive health, and nutritional support. The portfolio also extends to various personal care items, including daily body lotions, anti-itch formulations, moisturizing and soothing creams, body and foot care products, and powders specifically for eczema. Beyond its current offerings, Sanofi maintains a robust pipeline of pharmaceutical compounds and vaccines actively undergoing development. Strategic partnerships are also a cornerstone of Sanofi's approach. Significant collaborations include a joint effort with Glaxo. Smith. Kline to develop a recombinant Covid-19 vaccine, and a research alliance with Stanford University School of Medicine aimed at advancing immunology and inflammation knowledge through open scientific exchange. Additionally, it holds a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the enterprise operated under the name Sanofi-Aventis until its rebranding to Sanofi in May 2011.
Sanofi is a global pharmaceutical and healthcare enterprise dedicated to the discovery, development, manufacturing, and commercialization of therapeutic solutions, serving patients and consumers across the United States, Europe, and various international territories. Its business activities are structured across three primary segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The Pharmaceuticals division delivers a broad portfolio of specialty care products. These encompass cutting-edge human monoclonal antibodies, alongside treatments for complex conditions like multiple sclerosis, neurological issues, diverse inflammatory and immunological ailments, rare diseases, oncology, and rare blood disorders. Furthermore, this segment provides medications for diabetes and cardiovascular health, as well as a range of established prescription drugs. Sanofi's Vaccines division is a key provider of vital immunizations. Its offerings include pediatric vaccinations against poliomyelitis, pertussis, and Hib, alongside adult vaccines for influenza, booster shots, meningitis, and specialized immunizations for travel and endemic areas. Through its Consumer Healthcare segment, the company markets a diverse assortment of over-the-counter remedies. These solutions address areas such as allergy relief, cough and cold symptoms, pain management, liver care, physical and mental wellness, probiotics, digestive health, and nutritional support. The portfolio also extends to various personal care items, including daily body lotions, anti-itch formulations, moisturizing and soothing creams, body and foot care products, and powders specifically for eczema. Beyond its current offerings, Sanofi maintains a robust pipeline of pharmaceutical compounds and vaccines actively undergoing development. Strategic partnerships are also a cornerstone of Sanofi's approach. Significant collaborations include a joint effort with Glaxo. Smith. Kline to develop a recombinant Covid-19 vaccine, and a research alliance with Stanford University School of Medicine aimed at advancing immunology and inflammation knowledge through open scientific exchange. Additionally, it holds a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the enterprise operated under the name Sanofi-Aventis until its rebranding to Sanofi in May 2011.